First in the worldwide! Oral powder T-1101 approved by the US FDA to start Phase I clinical study
2016.09.30
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 Investigational New Drug Application
